M.D.C. (MDC) Set to Announce Quarterly Earnings on Thursday

M.D.C. (NYSE:MDC) will announce its earnings results before the market opens on Thursday, November 1st. Analysts expect the company to announce earnings of $0.97 per share for the quarter.

M.D.C. (NYSE:MDC) last released its quarterly earnings results on Wednesday, August 1st. The construction company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.27. M.D.C. had a return on equity of 13.82% and a net margin of 6.91%. The company had revenue of $749.60 million for the quarter, compared to analyst estimates of $713.27 million. During the same quarter in the prior year, the firm posted $0.64 EPS. M.D.C.’s quarterly revenue was up 15.5% compared to the same quarter last year. On average, analysts expect M.D.C. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

NYSE:MDC opened at $26.98 on Tuesday. M.D.C. has a fifty-two week low of $25.14 and a fifty-two week high of $37.45. The firm has a market cap of $1.58 billion, a P/E ratio of 10.46, a P/E/G ratio of 0.40 and a beta of 1.43. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.49 and a current ratio of 9.59.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 21st. Investors of record on Wednesday, November 7th will be issued a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 6th. This represents a $1.20 annualized dividend and a yield of 4.45%. M.D.C.’s payout ratio is presently 46.51%.

Several analysts recently weighed in on MDC shares. Zacks Investment Research lowered M.D.C. from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. ValuEngine lowered M.D.C. from a “hold” rating to a “sell” rating in a report on Saturday, September 22nd. Bank of America upgraded M.D.C. from an “underperform” rating to a “buy” rating and increased their price target for the company from $36.00 to $42.00 in a report on Thursday, August 2nd. Finally, JPMorgan Chase & Co. lowered M.D.C. from a “neutral” rating to an “underweight” rating and decreased their price target for the company from $38.00 to $32.00 in a report on Friday, September 21st. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $34.00.

In other M.D.C. news, Chairman Larry A. Mizel sold 10,000 shares of the company’s stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $33.15, for a total value of $331,500.00. Following the transaction, the chairman now owns 121,867 shares of the company’s stock, valued at approximately $4,039,891.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael A. Berman sold 20,000 shares of the company’s stock in a transaction on Thursday, August 23rd. The shares were sold at an average price of $32.67, for a total value of $653,400.00. Following the completion of the transaction, the director now directly owns 131,867 shares in the company, valued at approximately $4,308,094.89. The disclosure for this sale can be found here. Insiders have sold a total of 50,000 shares of company stock worth $1,637,300 in the last 90 days. 27.00% of the stock is currently owned by insiders.

M.D.C. Company Profile

M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.

See Also: Diversification in Investing

Earnings History for M.D.C. (NYSE:MDC)

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply